EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer
Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
EUCROSS is a phase II trial to evaluate the efficacy and safety of crizotinib in patients
with adenocarcinoma of the lung harbouring ROS1 translocations. Patients will be treated with
250mg crizotinib bid until progression or intolerable toxicity.